Kornimate/medical-research-clean huggingface dataset:
parkinson's disease and gamma-transcranial alternating current stimulation

Conditions: Parkinson Disease

Summary: cortical-basal ganglia gamma oscillations are pathologically reduced in parkinson's disease (pd) and the plasticity of the primary motor cortex (m1) is impaired. enhancing gamma oscillations through transcranial alternating current stimulation (tacs), a non-invasive neurophysiological tool that modulates cortical rhythms, can restore this alteration. however, whether tacs-related normalization of m1 plasticity results in positive clinical effects is unknown. motor learning is also impaired in pd and gamma oscillations play a relevant role in different forms of learning in humans. nevertheless, whether motor learning abnormalities relate to reduced gamma oscillations in pd is another unclear issue. it can be hypothesized that gamma oscillations impairment in m1 contributes to altered motor control, plasticity and learning in pd. accordingly, in this project, the authors intend to test whether gamma-tacs on m1 in pd patients ameliorates motor performance and learning, as objectively assessed with kinematic techniques.


Eligibility criteria:
inclusion criteria: * pd diagnosis exclusion criteria: * severe cognitive and psychiatric comorbidities * h\&y\>3 * levodopa-induced dyskinesia and tremor-dominant phenotype * history of additional neuropsychiatric disorders * intake of medications acting on brain excitability or plasticity * contraindications to non-invasive brain stimulation

Keywords: parkinson's disease motor cortex transcranial magnetic stimulation
initial education for rehabilitation and motivation program following a myocardial infarction via sms or hospital

Conditions: Acute Myocardial Infarction

Summary: the innovation in this preliminary study is the use of message reminders in patients after myocardial infarction in stage i of rehabilitation (ie discharge from hospital) at home via sms, compared with studies of patients undergoing cardiac rehabilitation (stage ii)in the hospital physiotherapy department.

the first stage of rehabilitation begins during hospitalization. motivation for the rehabilitation process for the patient. at this stage there will be preparation for release and guidance for the patient and their families regarding secondary prevention and return to domestic activity. this stage includes mobility, walking, controlled motility and gradual joint activation to maintain ranges and prevent complications from prolonged immobilization in bed.

Eligibility criteria:
inclusion criteria: informed consent criteria for inclusion patients after acute myocardial infarction admitted to the intensive care unit patients who speak the hebrew language patients with a cell phone to receive a reminder using a message exclusion criteria: orthopedic or neurological problem that would prevent physical activity. a score lower than 24 in the moca test. high-risk patients. complications: of myocardial infarction congestive heart failure, cardiogenic shock and / or ventricular arrhythmias. angina or shortness of breath at rest. decrease \>1mm in the st segment in the ecg.
comparison of vascular access in stemi

Conditions: ST Elevation Myocardial Infarction

Summary: distal radial access (dra) has recently introduced and previous studies have demonstrated that it is feasible option, showing several advantages including less bleeding and access-site complications over proximal radial access (pra). previous study reported the feasibility of dra as an alternative option for primary percutaneous coronary intervention (pci) in stemi patients without major complication. however, comparison study of each vascular access for primary pci have not been conducted until now. here, the investigators aim to compare the dra, pra and femoral access (fa), in terms of feasibility and safety, in patients with stemi. this is a retrospective study with patients who underwent primary pci for stemi between march 2020 to may 2021. the primary outcome of this study is the access-site complication including major bleeding requiring transfusion or surgery, hematoma and arterial occlusion.

recently, dra has gained the interest of interventional cardiologists and previous studies have demonstrated several advantages including patient and operator comfort, shorter hemostasis duration, less bleeding, and access-site complications over pra. more recently, randomized trial demonstrated that dra prevents radial artery occlusion after the procedure compared with pra. from this perspective, dra could be considered an alternative access route for primary pci in selected stemi patients using potent p2y12 inhibitors such as ticagrelor or prasugrel, or glycoprotein iib/iiia inhibitors.

Eligibility criteria:
inclusion criteria: * between march 2020 to may 2021, patients who underwent primary pci for stemi at the yongin severance hospital exclusion criteria: * refractory cardiogenic shock requiring extracorporeal membrane oxygenation (ecmo)

Keywords: distal radial access snuffbox approach st elevation myocardial infarction
the prevalence of hearing loss among children with congenital hypothyroidism

Conditions: Congenital Hypothyroidism; Hearing Loss

Summary: congenital hypothyroidism (ch) occurs in 1:4000 live births. neurological disturbances like speech delay, motor delay and lower iq were reported in children with ch. evidence from animal experiments indicate that ch is associated with high frequency of deafness. morphological changes of the external and internal cholera hairs were reported in mutagenic mice with ch. anatomical changes of the internal ear and low hearing threshold were reported in mice bearing dual oxidase 2 (duox2) gene mutations, which is responsible of oxidation of iodide. knockout of pax8 gene in mice resulted in both agenesis of thyroid gland and deafness. early l-thyroxin therapy prevented the development of deafness in those mice. the expression of thyroid receptor α (trα) in the external and internal cholera hairs in mice indicates that the thyroid hormones have an important role in the development of the internal ear. the etiology of deafness in human is both genetic and environmental. the prevalence of deafness in live births is 1:1000 and among them 60% is genetic. connexin 26 gene mutations are the most common cause of inherited deafness and account for about 40% of the genetic cases. in two conditions in human the coexistence of hypothyroidism and deafness were reported; pendred syndrome and thyroid hormone resistance syndrome. the prevalence of hearing loss in human with ch was explored in only few studies and the results are contrary. the aim of the current study is to study the prevalence of hearing loss among children with ch and to compare the clinical, biochemical and genetic characteristics between subjects with hearing loss to those without hearing loss.


Eligibility criteria:
inclusion criteria: * patients with congenital hypothyroidism aged 2-30 years exclusion criteria: * hearing defects in the family * intrauterine infections * perinatal hypoxia * long term therapy with aminoglycosides * acoustic trauma in the past

Keywords: congenital hypothyroidism(ch) hearing loss among children with ch
safety and efficacy of exenatide once weekly injection versus metformin, dipeptidyl peptidase-4 inhibitor, or thiazolidinedione as monotherapy in drug-naive patients with type 2 diabetes (duration-4)

Conditions: Type 2 Diabetes Mellitus

Summary: this study will compare the effects of 2.0 mg exenatide once weekly injection as monotherapy to 3 active comparators(metformin, dipeptidyl peptidase-4 inhibitor, and thiazolidinedione) in drug naive patients with type 2 diabetes treated with diet and exercise.


Eligibility criteria:
inclusion criteria: * have type 2 diabetes and are treated with diet and exercise alone. * at least 18 years of age. * hba1c between 7.1% and 11.0%, inclusive. * body mass index (bmi) of 23 kg/m2 to 45 kg/m2, inclusive. * have a history of stable body weight (not varying by \>5% for at least 3 months prior to screening). exclusion criteria: * have history of cardiac disease or presence of active cardiac disease within the year prior to inclusion in the study including myocardial infarction, clinically significant arrhythmia, unstable angina, moderate to severe congestive heart failure, coronary artery bypass surgery, or angioplasty * have a history of renal transplantation or are currently receiving renal dialysis * have active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years. * have history of severe gi disorder (e.g., gastroparesis) * have a history of acute or chronic pancreatitis. * have active proliferative retinopathy. * have been treated with drugs that promote weight loss (e.g., xenical®\[orlistat\], meridia® \[sibutramine\], acomplia® \[rimonabant\], acutrim® \[phenylpropanolamine\], or similar over-the-counter medications) within 3 months of screening. * have been treated with any antidiabetic agent for more than 7 days within 3 months prior to screening. * have had an organ transplant. * have previously completed or discontinued study drug in this study, withdrawn from this study or any other study investigating exenatide once weekly. * have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. * are currently enrolled in any other clinical study.

Keywords: amylin lilly exenatide once weekly byetta januvia sitagliptin thiazolidinedione
a study to evaluate the safety and efficacy of gatifloxacin for the treatment of bacterial conjunctivitis

Conditions: Bacterial Conjunctivitis

Summary: this is a 7 day study to evaluate the safety and efficacy of topical gatifloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in subjects from birth to 31 days of age


Eligibility criteria:
inclusion criteria: * diagnosed with bacterial conjunctivitis exclusion criteria: * chemical or foreign body trauma to either eye * infection in either eye (besides bacterial conjunctivitis) * white spots in the cornea or ulcers in either eye * clinical diagnosis of chlamydia or gonorrhea in either eye
a study of baricitinib (ly3009104) in participants with moderate-to-severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to evaluate the safety and effectiveness of baricitinib in eczema.


Eligibility criteria:
inclusion criteria: * have moderate-to-severe atopic dermatitis (ad), as determined by all of the following: 1. easi of 12 or more 2. greater than or equal to 10% of body surface area involvement 3. diagnosed with ad at least 2 years prior * have a history of inadequate clinical response to other eczema treatments exclusion criteria: * females who are pregnant or nursing * participants who do not agree to use adequate contraception * are currently experiencing or have a history of: * skin conditions such as psoriasis or lupus erythematosus * skin disease that requires frequent hospitalizations or intravenous treatment * compromised immunity * serious illness that could interfere with study participation, or a clinically important deviation in physical examination, vital sign measurements, electrocardiograms, or abnormalities on laboratory tests * currently experiencing or have a history of: * active or latent tuberculosis or specific immunity disorders and infections * malignancy or lymphoproliferative diseases in the last 5 years (or cervical, basal or squamous skin cancer re-occurrence in the last 3 years) * human immunodeficiency virus (hiv) * hepatitis b, hepatitis c, or chronic liver disease * have received certain types of vaccinations

Keywords: atopic eczema
hyaluronic acid, corticosteroid and electrotherapy in subacromial impingement syndrome

Conditions: Subacromial Impingement; Pain, Shoulder

Summary: background: electrotherapy, corticosteroid, and hyaluronic acid have been used to treat subacromial impingement syndrome. however, we need to compare treatment options to provide the optimal results. this study aims to compare the effect of hyaluronic acid, corticosteroid, and electrotherapy in subacromial impingement syndrome. design: ninety five patients were randomised into three equal groups according to treatment types. hyaluronic acid (20 mg/2ml, three times one week apart) or corticosteroid (triamcinolone acetonide, 40 mg/ml, single dose) treatments were applied as subacromial injections. electrotherapy consisted of 14 sessions tens (20 min.), hotpack (20 min.) and ultrasound (1.5watt/cm2, 1 mhz, 6 min.). patients were evaluated before treatment, one and four weeks post end of treatment. visual analogue scale (vas), range of motion (rom), and shoulder disability questionnaire (sdq) were used as outcome measures.


Eligibility criteria:
inclusion criteria: * the diagnosis of subacromial impingement syndrome exclusion criteria: * patients aged \ 50 years or who have the following medical conditions were excluded: physical therapy or injection in the past 6 months, shoulder instability, acute trauma, adhesive capsulitis, psychiatric illness, diabetes mellitus, malignancy.
pilot study on the effectiveness and safety of optilene® silver mesh elastic in prevention of surgical site infection (ssi) and incisional hernia (ih)

Conditions: Abdominal Aortic Aneurysm; Morbid Obesity

Summary: the aim of the study is to describe the effectiveness of optilene® silver mesh elastic on prevention of surgical site infection (ssi) at 6 months follow-up in patients undergoing urgent laparotomy by collecting clinical data on the ssi rates, ih rates and overall clinical performance of optilene® silver mesh elastic used for the prevention of incisional hernia as prophylactic mesh in patients that require urgent median laparotomy in clinical routine.


Eligibility criteria:
inclusion criteria: * adult patients (18 years or older) * surgical procedure requiring urgent, primary median laparotomy, which are classified as "class iii/contaminated" or "class iv/dirty-infected" regarding the cdc classification. these include but are not limited to: * vascular surgery * colon and rectum * hepatobiliary * gastrointestinal * gynecology * urology * abdominal aortic aneurysm (aaa) repair * right hemicolectomy * left hemicolectomy * sigmoidectomy * anterior resection * abdominoperineal amputation * exploratory laparotomy * cholecystectomy * cholecystectomy and choledocotomy * written informed consent exclusion criteria: * pregnancy * breast feeding * patients \< 18 years old or patients who are still in the growth phase * contaminated and infected areas * hypersensitivity to silver * direct contact with the viscera * previous allergic reactions to components of the device * patient with previous laparotomy * transverse laparotomy * patients with previous hernia repair * simultaneous participation in another investigational clinical trial (drug or medical studies) * patients with active oncologic treatment (chemo and radiotherapy) * underlying autoimmune disease * recent cardiovascular complication * gynecology surgery * urology surgery * vascular surgery

Keywords: urgent, primary median laparotomy
oral cancer screening and education in hong kong

Conditions: Oral Cancer; Oral Leukoplakia; Oral Submucous Fibrosis; Proliferative Verrucous Leukoplakia; Oral Erythroplakia; Erosive Lichen Planus

Summary: this study will be conducted to obtain data on oral cancer risk factors to generate machine learning models with good predictive accuracy for stratifying individuals with high-oral cancer risk and delineating high-risk and low-risk oral lesions. likewise, this study will seek to provide oral cancer-related health education and training on oral-self-examination for beneficiaries


Eligibility criteria:
inclusion criteria: * healthy individuals satisfying age and residential area criteria with no previous history of oral cancer. individuals with a history of other cancers will be included in the study provided they have been in remission for more than three years. exclusion criteria: * participants with reduced mouth opening (irrespective of the cause) to permit proper administration of voe or photosensitive epilepsy will be excluded. likewise, those who decline the provision of written consent or participation in any part of the study.
africa and middle east cardiovascular epidemiological study

Conditions: Obesity; Smoking; Dyslipidemia; Diabetes Mellitus; Hypertension

Summary: this is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending general practice clinics in the africa and middle east region. a total of 4300 patients will be evaluated. in patients who are found to have previously been diagnosed with cardiovascular (cv) risk factors such as dyslipidemia or hypertension, the level of control of their respective conditions will also be evaluated.

this is a cross-sectional, epidemiological study. in the course of this study, 4,300 persons from general practice, and other non specialist clinics of selected countries of the africa and middle east region, will be evaluated for the presence of cardiovascular (cv) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension. the degree of control of hypertension and dyslipidaemia in those previously diagnosed with these conditions will also be assessed. all medications used for cv risk factor control will also be ascertained. patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study.

Eligibility criteria:
inclusion criteria: * adult aged 18 or above exclusion criteria: * pregnant women and/or lactating mothers * subjects presenting with any life threatening disease/condition

Keywords: cross-sectional epidemiological study to evaluate the prevalence of cv risk factors in patients attending general practice in afme region
german ablation quality-register

Conditions: Arrhythmia

Summary: the goal of this register is the documentation of the success as well as of the complications regarding interventional therapy of cardiac arrhythmia by catheter ablation. this is the necessary basis for quality management and development of possible improvements of catheter ablation.

the interventional therapy of heartbeat disturbances by means of catheter ablation makes the curative treatment possible of numerous tachycardiac arrhythmics. by this crucial improvement of the supply of patients and its quality of life a genuine healing of a multiplicity of heartbeat disturbances became possible. especially within the range of the ablation treatment there are relatively few con-trolled studies, which would give a broad collection of the results of the catheter ablation in the different indication areas. aim of the registry: documentation of indication, hospital course and complications during long term follow-up of patients with catheter ablation design: prospective, multicenter registry; fu-duration 12 months. duration: phase i: 2 years inclusion criteria: catheter ablation (intention to treat) exclusion criteria: missing declaration of consent

Eligibility criteria:
inclusion criteria: * the ablation register will include all consecutive patients with a performed or attempted electrophysiological ablation exclusion criteria: * missing signed informed consent

Keywords: cardiac arrhythmia catheter ablation register
second-line treatment in patients with small cell lung cancer (sclc)

Conditions: Small Cell Lung Cancer

Summary: the purpose of this study is to determine treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy.

determined treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy.

Eligibility criteria:
inclusion criteria: * small-cell lung cancer. * patients who, after (at least) a first line of chemotherapy based on platinum, had a partial response and then progressed, or who had a complete response and then relapsed within three months following the last course of this first-line therapy. * measurable or assessable disease. * life expectancy \>2 months. * patients with a therapeutic risk level of \<5 points (see section 6: "treatment flowchart"). * age \>18 years; * performance status (who) \<2; * one measurable target lesion in a non irradiated region; * prior radiotherapy authorized unless it targeted the only measurable lesion; * biological criteria: wbc \>2000/mm3, pmn \>1500/mm3, platelets \>100 000/mm3, creatinemia \<2 x uln, bilirubinemia \<uln, alt and ast \<2.5 x uln (\< 5 n if liver metastases) * normal ecg * written informed consent. exclusion criteria: * non small-cell lung cancer. * no objective response to platinum-based therapy * complete response lasting more than three months after the last course of first-line treatment. * symptomatic brain metastases. * bone metastases, carcinomatous lymphangitis, ascites or pleurisy as sole assessable disease manifestations.- concurrent participation in another clinical trial. * therapeutic risk level of 6 points or more (see table) * uncontrolled clotting disorders; * uncontrolled severe infection; * history of another malignancy, except for cervical carcinoma in situ or basocellular cancer that are considered cured; * psychological, familial, sociological or geographic circumstances preventing treatment follow-up as defined in the protocol; * patients deprived of their rights for administrative or legal reasons.

Keywords: cancer lung cancer small-cell lung cancer
early treatment outcomes in pierre-robin-like phenotype

Conditions: Pierre Robin Syndrome

Summary: in a longitudinal cohort study, we want to assess the effect of the pre-epiglottic baton plate, the main treatment approach currently used in germany for pierre-robin-like phenotype, on upper airway obstruction and failure to thrive using objective criteria (mixed-obstructive apnea index assessed by polysomnography, standard deviation score for body weight) upon admission and 3 months after hospital discharge.

pierre-robin sequence consists of a small lower jaw, a retropositioned tongue (glossoptosis), and optionally cleft palate, leading to severe upper airway obstruction and failure to thrive; occasionally even to sudden infant death. treatment approaches are heterogeneous, some are considerably invasive; few have been evaluated by objective tests. in a longitudinal cohort study, we want to assess the effect of the pre-epiglottic baton plate on upper airway obstruction and failure to thrive using objective criteria (mixed-obstructive apnea index assessed by polysomnography, standard deviation score for body weight) upon admission and 3 months after hospital discharge. the pre-epiglottic baton plate is the main treatment approach currently used in germany for this condition and practised standard care in the three participating study centers. these data will help to compare the effect of the main treatment currently used in germany with international data on more invasive treatments used in this rare condition.

Eligibility criteria:
inclusion criteria: * infants \< 1 year at admission, pierre-robin-like phenotype exclusion criteria: * no parental consent; need for immediate tracheotomy

Keywords: upper airway obstruction